The Most Important Charts In The Market… Plus Tracking Weight Loss Drug Supply 6/4/24

Shares of FedEx soaring after its latest earnings report. The numbers behind the move and all the details out of the conference call. Plus, all things housing taking a hit, as economists forecast a “stuck” market for the next few years. And it’s not just the builders feeling the pain. The related names seeing some losses.  Fast Money Disclaimer 

Nvidia notching another day of losses, but the broader markets aren’t taking it too hard. How investors are handling the semi slide. Plus A big jump for one biopharma stock as Alnylam delivers promising new heart drug results. What the CEO had to say about the data, and the impact it could have on the space. Fast Money Disclaimer

Has the fever broken for the high momentum stocks? Nvidia running out of steam this week, as some other high fliers also pull back. Is this just a bump in the road or the beginning of a summer slowdown? Plus Sarepta’s big surge. The biotech company getting expanded approval from the FDA for its muscular dystrophy drug. What the CEO says is next for the company. Fast Money Disclaimer 

Some of this year’s red hot stocks have seemed to hit a wall. Nvidia, Chipotle, Netflix… all taking a leg lower in today’s session. Is the pullback temporary? Or could there be more downside ahead. Plus Gilead’s big boost. Shares jumping after the biotech company’s latest trial results. What the data could mean in the fight against HIV. Fast Money Disclaimer 

There’s a new biggest bull on Wall Street, as Evercore’s Julian Emanuel ups his year-end price target on the S&P by 25% to a whopping 6,000/ What’s going to drive those returns and how should you play the market? Plus Industrials have been struggling so far in 2024, but one top technician says these names are about to witness a turnaround. We go off the charts to get the details. Fast Money Disclaimer 

There’s a new biggest bull on Wall Street, as Evercore’s Julian Emanuel ups his year-end price target on the S&P by 25% to a whopping 6,000/ What’s going to drive those returns and how should you play the market? Plus Industrials have been struggling so far in 2024, but one top technician says these names are about to witness a turnaround. We go off the charts to get the details. Fast Money Disclaimer

Apple and Netflix both having strong weeks as the stocks trade near record highs. What’s next for the names and what could their rise mean for the rest of the markets? Plus long-struggling Gilead getting a boost today on early results of its experimental obesity pill. Can it effectively compete with the likes of Eli Lilly and Novo Nordisk? Fast Money Disclaimer

Tesla shareholders voting on CEO Elon Musk’s pay package. The billions that could come his way, and if the EV maker’s incorporation will stay in Delaware or head to the lone star state. Plus Media stocks in the red as the future of television and streaming continue to evolve. What the stock moves could be telling us about the media landscape. Fast Money Disclaimer

Another pause out of Powell, as the Federal Reserve leaves rates unchanged, noting some progress on inflation. What the central bank is forecasting for rate cuts this year. Plus The rate decision’s impact on financial stocks. Why one top bank analyst says it could be a boost for the group. Fast Money Disclaimer

Shares of Apple jumping to record highs just a day after falling flat on its new AI announcements. The turnaround for the tech titan, and what it means for the market. Plus The weight loss wars rage on… and we’re honing in on oral version of GLP-1’s. How one pharma stock is faring in the space, and how their results stack up against the competition. Fast Money Disclaimer